Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890012) titled 'Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)' on Oct. 16.

Study Type: Observational

Primary Sponsor: Hospices Civils de Lyon

Condition: Well-Differentiated Neuroendocrine Tumors (NETs)

Intervention: Other: PRO-CSS questionnaire

Recruitment Status: Not recruiting

Date of First Enrollment: January 1, 2027

Target Sample Size: 100

Countries of Recruitment: France

To know more, visit https://clinicaltrials.gov/study/NCT07890012

Disclaimer: Curated by HT Syndication....